These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 532698)

  • 1. Effect of protein and peptide fractions from the peritoneal dialysate of patients with chronic renal failure on the lipoprotein lipase activity.
    Lutz W
    Acta Med Pol; 1979; 20(2):131-41. PubMed ID: 532698
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of strongly basic uremic peptide on liberation of lipoprotein lipase activity from human adipose cells.
    Lutz W
    Acta Med Pol; 1976; 17(1):55-70. PubMed ID: 1258692
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
    Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
    Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis].
    Grzegorzewska A; Antoniewicz K; Kuźniak J; Zawadzka E
    Przegl Lek; 1990; 47(10):686-90. PubMed ID: 2089444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disorders of protein and lipid metabolism associated with chronic renal failure and chronic dialysis.
    Krumlovsky FA
    Ann Clin Lab Sci; 1981; 11(4):350-60. PubMed ID: 7023349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum lipase concentration in chronic hemodialysis patients.
    Mashayekhi SO; Ghandforoush-Sattari M; Rahimipour A
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1143-4. PubMed ID: 21060192
    [No Abstract]   [Full Text] [Related]  

  • 7. Peroxidase activity in peritoneal neutrophils of patients with terminal renal failure treated by intermittent peritoneal dialysis.
    Sułowicz W; Hanicki Z; Labza H; Basta A
    Med Interne; 1990; 28(2):135-8. PubMed ID: 2176739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indoprofen in chronic intermittent peritoneal dialysis: effects in the clearance of small molecules and protein loss].
    García-Ortiz R; Campos G; Silva G; Gómez M; Uribe C; Herrera O
    Rev Med Chil; 1989 May; 117(5):528-33. PubMed ID: 2519164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phagocytic activity of neutrophils from the peritoneal dialysate of patients with chronic renal failure treated by intermittent peritoneal dialysis.
    Sułowicz W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):325-30. PubMed ID: 1697837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products in renal failure.
    Thornalley PJ
    J Ren Nutr; 2006 Jul; 16(3):178-84. PubMed ID: 16825015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytomorphological, cytochemical and functional characteristics of cells from peritoneal dialysate of patients with terminal renal failure treated by intermittent peritoneal dialysis. IV. Cytochemical studies of acid phosphatase, beta-glucuronidase and N-acetyl-beta-D-glucosaminidase activity].
    Sułowicz W
    Przegl Lek; 1987; 44(9):642-9. PubMed ID: 3438477
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytomorphologic, cytochemical and functional characteristics of cells from the peritoneal dialysate of patients with terminal renal failure treated by intermittent peritoneal dialysis. I. Quantitative and qualitative characteristics of the cells of the peritoneal dialysate].
    Sułowicz W
    Przegl Lek; 1987; 44(3):326-35. PubMed ID: 3615937
    [No Abstract]   [Full Text] [Related]  

  • 13. [Absorption of ceftizoxime from peritoneal dialysate and its pharmacokinetics in chronic kidney failure patients].
    Gao S; Li P; Liu GL; Wang SX; Chui RL; Yang JP
    Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):377-80. PubMed ID: 1456067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of some lysosomal enzymes in peritoneal macrophages of patients with end-stage renal failure treated by intermittent peritoneal dialysis.
    Sułowicz W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(5):663-7. PubMed ID: 1709899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal exchange volume and dialysate flow rate in peritoneal dialysis. A clinical study.
    Kalra OP; Abrol L; Chopra JS; Agarwal SK; Prakash C
    J Assoc Physicians India; 1989 Dec; 37(12):762-4. PubMed ID: 2699986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipid metabolism disorders in chronic kidney failure].
    Lacour B; Roullet JB; Drueke T
    Nephrologie; 1983; 4(2):75-83. PubMed ID: 6348572
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum lipase and amylase levels in chronic renal failure: interpretation of results--effects of extrarenal purification].
    Thierry FX; Dueymes JM; Vernier I; Fauvel J; Meeus F; Meurisse JJ; Pene C; Conte JJ
    Nephrologie; 1988; 9(6):263-7. PubMed ID: 2467218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of furosemide added to peritoneal dialysis fluid on hydroxyproline excretion in dialysate and urine].
    Sucharzewska-Tomczak M; Grzegorzewska A
    Przegl Lek; 1994; 51(7):300-2. PubMed ID: 7871203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation.
    Wanner C; Förstner-Wanner S; Rössle C; Fürst P; Schollmeyer P; Hörl WH
    Kidney Int Suppl; 1987 Oct; 22():S132-5. PubMed ID: 3480977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.